lenticrispr v2 plasmids Search Results


96
Addgene inc lentiviral vector lenticrispr v2
(A) Ter119 negative cells and Ter119 positive erythroid cells were purified from wild-type mouse bone marrow cells. G4 levels were tested by flow cytometry using the BG4 antibody that specifically recognizes G4. Quantification is on the right. (B) Bone marrow lineage-negative cells were cultured in Epo medium for 2 days. G4 levels were tested on different days using flow cytometry by the BG4 antibody. Quantification is on the right. (C) CD34+ human HSPCs were cultured in Epo medium for 21 days. The levels of G4 were measured by flow cytometry as in B at the indicated time. Cells at day 7, 14, and 21 represent proerythroblasts, polychromatic to orthochromatic erythroblasts, and orthochromatic to mature red blood cells, respectively. (D) Flow cytometric assays of G4 levels in the indicated bone marrow lineage cells purified from wild-type mice. (E) Quantification of D. (F) Gating strategy of various erythroblasts. Populations I to VI represent proerythroblasts, basophilic erythroblasts, polychromatic erythroblasts, orthochromatic erythroblasts, late orthochromatic to reticulocytes, and mature red blood cells, respectively. (G-H) Flow cytometric assay of G4 level in bone marrow erythroid populations I (G) and V (H) from the indicated mice. Quantification is on the right. (I) Bone marrow lineage negative cells from the indicated mice were cultured in Epo medium for 2 days. G4 levels on different days were measured by flow cytometry using BG4 antibody. Quantification is below the histogram. (J) CD34+ cells were transduced with <t>lentiviral</t> vectors expressing indicated sgRNAs and <t>Cas9.</t> Cells were then harvested for Western blotting of the indicated proteins at day 9 in culture. (K) Quantitative analyses of G4 levels in cells from J using flow cytometric assays. (L) Quantitative analyses of cell death in cells from J using flow cytometric assays. The dead cells are defined as propidium iodide and annexin V double positive. (M) Quantitative analyses of G4 levels in bone marrow mononuclear cells from the patient with DDX41 mutated MDS. All the error bars represent the SEM of the mean. The comparison between two groups was evaluated with 2 tailed t tests, and the comparison among multiple groups was evaluated with 1-way ANOVA tests. * p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. ns: not significant.
Lentiviral Vector Lenticrispr V2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lentiviral vector lenticrispr v2/product/Addgene inc
Average 96 stars, based on 1 article reviews
lentiviral vector lenticrispr v2 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

96
Addgene inc lenticrispr v2 blast vector
(A) Ter119 negative cells and Ter119 positive erythroid cells were purified from wild-type mouse bone marrow cells. G4 levels were tested by flow cytometry using the BG4 antibody that specifically recognizes G4. Quantification is on the right. (B) Bone marrow lineage-negative cells were cultured in Epo medium for 2 days. G4 levels were tested on different days using flow cytometry by the BG4 antibody. Quantification is on the right. (C) CD34+ human HSPCs were cultured in Epo medium for 21 days. The levels of G4 were measured by flow cytometry as in B at the indicated time. Cells at day 7, 14, and 21 represent proerythroblasts, polychromatic to orthochromatic erythroblasts, and orthochromatic to mature red blood cells, respectively. (D) Flow cytometric assays of G4 levels in the indicated bone marrow lineage cells purified from wild-type mice. (E) Quantification of D. (F) Gating strategy of various erythroblasts. Populations I to VI represent proerythroblasts, basophilic erythroblasts, polychromatic erythroblasts, orthochromatic erythroblasts, late orthochromatic to reticulocytes, and mature red blood cells, respectively. (G-H) Flow cytometric assay of G4 level in bone marrow erythroid populations I (G) and V (H) from the indicated mice. Quantification is on the right. (I) Bone marrow lineage negative cells from the indicated mice were cultured in Epo medium for 2 days. G4 levels on different days were measured by flow cytometry using BG4 antibody. Quantification is below the histogram. (J) CD34+ cells were transduced with <t>lentiviral</t> vectors expressing indicated sgRNAs and <t>Cas9.</t> Cells were then harvested for Western blotting of the indicated proteins at day 9 in culture. (K) Quantitative analyses of G4 levels in cells from J using flow cytometric assays. (L) Quantitative analyses of cell death in cells from J using flow cytometric assays. The dead cells are defined as propidium iodide and annexin V double positive. (M) Quantitative analyses of G4 levels in bone marrow mononuclear cells from the patient with DDX41 mutated MDS. All the error bars represent the SEM of the mean. The comparison between two groups was evaluated with 2 tailed t tests, and the comparison among multiple groups was evaluated with 1-way ANOVA tests. * p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. ns: not significant.
Lenticrispr V2 Blast Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrispr v2 blast vector/product/Addgene inc
Average 96 stars, based on 1 article reviews
lenticrispr v2 blast vector - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

93
Addgene inc lenticrispr v2 puro
(A) Ter119 negative cells and Ter119 positive erythroid cells were purified from wild-type mouse bone marrow cells. G4 levels were tested by flow cytometry using the BG4 antibody that specifically recognizes G4. Quantification is on the right. (B) Bone marrow lineage-negative cells were cultured in Epo medium for 2 days. G4 levels were tested on different days using flow cytometry by the BG4 antibody. Quantification is on the right. (C) CD34+ human HSPCs were cultured in Epo medium for 21 days. The levels of G4 were measured by flow cytometry as in B at the indicated time. Cells at day 7, 14, and 21 represent proerythroblasts, polychromatic to orthochromatic erythroblasts, and orthochromatic to mature red blood cells, respectively. (D) Flow cytometric assays of G4 levels in the indicated bone marrow lineage cells purified from wild-type mice. (E) Quantification of D. (F) Gating strategy of various erythroblasts. Populations I to VI represent proerythroblasts, basophilic erythroblasts, polychromatic erythroblasts, orthochromatic erythroblasts, late orthochromatic to reticulocytes, and mature red blood cells, respectively. (G-H) Flow cytometric assay of G4 level in bone marrow erythroid populations I (G) and V (H) from the indicated mice. Quantification is on the right. (I) Bone marrow lineage negative cells from the indicated mice were cultured in Epo medium for 2 days. G4 levels on different days were measured by flow cytometry using BG4 antibody. Quantification is below the histogram. (J) CD34+ cells were transduced with <t>lentiviral</t> vectors expressing indicated sgRNAs and <t>Cas9.</t> Cells were then harvested for Western blotting of the indicated proteins at day 9 in culture. (K) Quantitative analyses of G4 levels in cells from J using flow cytometric assays. (L) Quantitative analyses of cell death in cells from J using flow cytometric assays. The dead cells are defined as propidium iodide and annexin V double positive. (M) Quantitative analyses of G4 levels in bone marrow mononuclear cells from the patient with DDX41 mutated MDS. All the error bars represent the SEM of the mean. The comparison between two groups was evaluated with 2 tailed t tests, and the comparison among multiple groups was evaluated with 1-way ANOVA tests. * p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. ns: not significant.
Lenticrispr V2 Puro, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrispr v2 puro/product/Addgene inc
Average 93 stars, based on 1 article reviews
lenticrispr v2 puro - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Addgene inc lenticrispr v2 vector
(A) Ter119 negative cells and Ter119 positive erythroid cells were purified from wild-type mouse bone marrow cells. G4 levels were tested by flow cytometry using the BG4 antibody that specifically recognizes G4. Quantification is on the right. (B) Bone marrow lineage-negative cells were cultured in Epo medium for 2 days. G4 levels were tested on different days using flow cytometry by the BG4 antibody. Quantification is on the right. (C) CD34+ human HSPCs were cultured in Epo medium for 21 days. The levels of G4 were measured by flow cytometry as in B at the indicated time. Cells at day 7, 14, and 21 represent proerythroblasts, polychromatic to orthochromatic erythroblasts, and orthochromatic to mature red blood cells, respectively. (D) Flow cytometric assays of G4 levels in the indicated bone marrow lineage cells purified from wild-type mice. (E) Quantification of D. (F) Gating strategy of various erythroblasts. Populations I to VI represent proerythroblasts, basophilic erythroblasts, polychromatic erythroblasts, orthochromatic erythroblasts, late orthochromatic to reticulocytes, and mature red blood cells, respectively. (G-H) Flow cytometric assay of G4 level in bone marrow erythroid populations I (G) and V (H) from the indicated mice. Quantification is on the right. (I) Bone marrow lineage negative cells from the indicated mice were cultured in Epo medium for 2 days. G4 levels on different days were measured by flow cytometry using BG4 antibody. Quantification is below the histogram. (J) CD34+ cells were transduced with <t>lentiviral</t> vectors expressing indicated sgRNAs and <t>Cas9.</t> Cells were then harvested for Western blotting of the indicated proteins at day 9 in culture. (K) Quantitative analyses of G4 levels in cells from J using flow cytometric assays. (L) Quantitative analyses of cell death in cells from J using flow cytometric assays. The dead cells are defined as propidium iodide and annexin V double positive. (M) Quantitative analyses of G4 levels in bone marrow mononuclear cells from the patient with DDX41 mutated MDS. All the error bars represent the SEM of the mean. The comparison between two groups was evaluated with 2 tailed t tests, and the comparison among multiple groups was evaluated with 1-way ANOVA tests. * p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. ns: not significant.
Lenticrispr V2 Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrispr v2 vector/product/Addgene inc
Average 93 stars, based on 1 article reviews
lenticrispr v2 vector - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Addgene inc lenticrispr v2 h bak1
(A) Immunoblotting analysis of CASP3 expression in WM793 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (B) Quantification of the migration potential of parental and CASP3-deficient WM793 cells using various siRNAs, through wound area measurement (data represent mean with SD of a representative experiment). (C) Analysis by immunoblotting of CASP3 expression in WM852 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (D) Quantification of the migration potential of control and CASP3-deficient WM852 cells using various siRNAs through wound area measurement (data represent mean with SD of a representative experiment). (E) Analysis by immunoblotting of CASP3 expression in CRISPR/Cas9-edited WM793 cells, electroporated with either control or CASP3 -targetting sgRNAs. HSC70 serves as a loading control. (F) Quantification of the invasion potential of CRISPR/Cas9 control and CASP3 -targetted WM793 cells, through wound area measurement (data represent mean with SD of a representative experiment). (G-H) Same as in E-F, for WM852 cells. (I) Quantification of the migration potential of control and CASP3-deficient WM793 cells treated with the pan-caspase inhibitor qVD-OPh (10µM) through wound area measurement (data represent mean with SD of a representative experiment). (J-K) Measurement of caspase-3/7 activation in WM793 ( J ) and WM852 cells ( K ) expressing the caspase reporter VC3AI, and treated with actinomycin D (ActD, 1 µM), ABT-263 (5 µM) and qVD-OPh (10 µM) for 24 h. (L) Analysis by immunoblotting of BAX and BAK expression in BAX / <t>BAK1</t> double knock-out CRISPR/Cas9-edited WM793 cells. HSC70 serves as a loading control. (M-N) Quantification of the migration ( M ) and invasion ( N ) potential of CRISPR/Cas9 control and and BAX / BAK1 double knock-out WM793 cells (data represent mean with SD of a representative experiment).
Lenticrispr V2 H Bak1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrispr v2 h bak1/product/Addgene inc
Average 93 stars, based on 1 article reviews
lenticrispr v2 h bak1 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Addgene inc sgrna targeting bap1
(A) Immunoblotting analysis of CASP3 expression in WM793 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (B) Quantification of the migration potential of parental and CASP3-deficient WM793 cells using various siRNAs, through wound area measurement (data represent mean with SD of a representative experiment). (C) Analysis by immunoblotting of CASP3 expression in WM852 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (D) Quantification of the migration potential of control and CASP3-deficient WM852 cells using various siRNAs through wound area measurement (data represent mean with SD of a representative experiment). (E) Analysis by immunoblotting of CASP3 expression in CRISPR/Cas9-edited WM793 cells, electroporated with either control or CASP3 -targetting sgRNAs. HSC70 serves as a loading control. (F) Quantification of the invasion potential of CRISPR/Cas9 control and CASP3 -targetted WM793 cells, through wound area measurement (data represent mean with SD of a representative experiment). (G-H) Same as in E-F, for WM852 cells. (I) Quantification of the migration potential of control and CASP3-deficient WM793 cells treated with the pan-caspase inhibitor qVD-OPh (10µM) through wound area measurement (data represent mean with SD of a representative experiment). (J-K) Measurement of caspase-3/7 activation in WM793 ( J ) and WM852 cells ( K ) expressing the caspase reporter VC3AI, and treated with actinomycin D (ActD, 1 µM), ABT-263 (5 µM) and qVD-OPh (10 µM) for 24 h. (L) Analysis by immunoblotting of BAX and BAK expression in BAX / <t>BAK1</t> double knock-out CRISPR/Cas9-edited WM793 cells. HSC70 serves as a loading control. (M-N) Quantification of the migration ( M ) and invasion ( N ) potential of CRISPR/Cas9 control and and BAX / BAK1 double knock-out WM793 cells (data represent mean with SD of a representative experiment).
Sgrna Targeting Bap1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sgrna targeting bap1/product/Addgene inc
Average 93 stars, based on 1 article reviews
sgrna targeting bap1 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Addgene inc lenticrispr v2 hbax
(A) Immunoblotting analysis of CASP3 expression in WM793 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (B) Quantification of the migration potential of parental and CASP3-deficient WM793 cells using various siRNAs, through wound area measurement (data represent mean with SD of a representative experiment). (C) Analysis by immunoblotting of CASP3 expression in WM852 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (D) Quantification of the migration potential of control and CASP3-deficient WM852 cells using various siRNAs through wound area measurement (data represent mean with SD of a representative experiment). (E) Analysis by immunoblotting of CASP3 expression in CRISPR/Cas9-edited WM793 cells, electroporated with either control or CASP3 -targetting sgRNAs. HSC70 serves as a loading control. (F) Quantification of the invasion potential of CRISPR/Cas9 control and CASP3 -targetted WM793 cells, through wound area measurement (data represent mean with SD of a representative experiment). (G-H) Same as in E-F, for WM852 cells. (I) Quantification of the migration potential of control and CASP3-deficient WM793 cells treated with the pan-caspase inhibitor qVD-OPh (10µM) through wound area measurement (data represent mean with SD of a representative experiment). (J-K) Measurement of caspase-3/7 activation in WM793 ( J ) and WM852 cells ( K ) expressing the caspase reporter VC3AI, and treated with actinomycin D (ActD, 1 µM), ABT-263 (5 µM) and qVD-OPh (10 µM) for 24 h. (L) Analysis by immunoblotting of BAX and BAK expression in BAX / <t>BAK1</t> double knock-out CRISPR/Cas9-edited WM793 cells. HSC70 serves as a loading control. (M-N) Quantification of the migration ( M ) and invasion ( N ) potential of CRISPR/Cas9 control and and BAX / BAK1 double knock-out WM793 cells (data represent mean with SD of a representative experiment).
Lenticrispr V2 Hbax, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrispr v2 hbax/product/Addgene inc
Average 93 stars, based on 1 article reviews
lenticrispr v2 hbax - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

94
Addgene inc plenticrispr cas9 v2 vector
(A) Immunoblotting analysis of CASP3 expression in WM793 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (B) Quantification of the migration potential of parental and CASP3-deficient WM793 cells using various siRNAs, through wound area measurement (data represent mean with SD of a representative experiment). (C) Analysis by immunoblotting of CASP3 expression in WM852 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (D) Quantification of the migration potential of control and CASP3-deficient WM852 cells using various siRNAs through wound area measurement (data represent mean with SD of a representative experiment). (E) Analysis by immunoblotting of CASP3 expression in CRISPR/Cas9-edited WM793 cells, electroporated with either control or CASP3 -targetting sgRNAs. HSC70 serves as a loading control. (F) Quantification of the invasion potential of CRISPR/Cas9 control and CASP3 -targetted WM793 cells, through wound area measurement (data represent mean with SD of a representative experiment). (G-H) Same as in E-F, for WM852 cells. (I) Quantification of the migration potential of control and CASP3-deficient WM793 cells treated with the pan-caspase inhibitor qVD-OPh (10µM) through wound area measurement (data represent mean with SD of a representative experiment). (J-K) Measurement of caspase-3/7 activation in WM793 ( J ) and WM852 cells ( K ) expressing the caspase reporter VC3AI, and treated with actinomycin D (ActD, 1 µM), ABT-263 (5 µM) and qVD-OPh (10 µM) for 24 h. (L) Analysis by immunoblotting of BAX and BAK expression in BAX / <t>BAK1</t> double knock-out CRISPR/Cas9-edited WM793 cells. HSC70 serves as a loading control. (M-N) Quantification of the migration ( M ) and invasion ( N ) potential of CRISPR/Cas9 control and and BAX / BAK1 double knock-out WM793 cells (data represent mean with SD of a representative experiment).
Plenticrispr Cas9 V2 Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plenticrispr cas9 v2 vector/product/Addgene inc
Average 94 stars, based on 1 article reviews
plenticrispr cas9 v2 vector - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

90
GenScript corporation lenticrispr v2 plasmids
(A) Immunoblotting analysis of CASP3 expression in WM793 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (B) Quantification of the migration potential of parental and CASP3-deficient WM793 cells using various siRNAs, through wound area measurement (data represent mean with SD of a representative experiment). (C) Analysis by immunoblotting of CASP3 expression in WM852 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (D) Quantification of the migration potential of control and CASP3-deficient WM852 cells using various siRNAs through wound area measurement (data represent mean with SD of a representative experiment). (E) Analysis by immunoblotting of CASP3 expression in CRISPR/Cas9-edited WM793 cells, electroporated with either control or CASP3 -targetting sgRNAs. HSC70 serves as a loading control. (F) Quantification of the invasion potential of CRISPR/Cas9 control and CASP3 -targetted WM793 cells, through wound area measurement (data represent mean with SD of a representative experiment). (G-H) Same as in E-F, for WM852 cells. (I) Quantification of the migration potential of control and CASP3-deficient WM793 cells treated with the pan-caspase inhibitor qVD-OPh (10µM) through wound area measurement (data represent mean with SD of a representative experiment). (J-K) Measurement of caspase-3/7 activation in WM793 ( J ) and WM852 cells ( K ) expressing the caspase reporter VC3AI, and treated with actinomycin D (ActD, 1 µM), ABT-263 (5 µM) and qVD-OPh (10 µM) for 24 h. (L) Analysis by immunoblotting of BAX and BAK expression in BAX / <t>BAK1</t> double knock-out CRISPR/Cas9-edited WM793 cells. HSC70 serves as a loading control. (M-N) Quantification of the migration ( M ) and invasion ( N ) potential of CRISPR/Cas9 control and and BAX / BAK1 double knock-out WM793 cells (data represent mean with SD of a representative experiment).
Lenticrispr V2 Plasmids, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrispr v2 plasmids/product/GenScript corporation
Average 90 stars, based on 1 article reviews
lenticrispr v2 plasmids - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Lucigen Corp lenticrispr v2 plasmid
(A) Immunoblotting analysis of CASP3 expression in WM793 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (B) Quantification of the migration potential of parental and CASP3-deficient WM793 cells using various siRNAs, through wound area measurement (data represent mean with SD of a representative experiment). (C) Analysis by immunoblotting of CASP3 expression in WM852 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (D) Quantification of the migration potential of control and CASP3-deficient WM852 cells using various siRNAs through wound area measurement (data represent mean with SD of a representative experiment). (E) Analysis by immunoblotting of CASP3 expression in CRISPR/Cas9-edited WM793 cells, electroporated with either control or CASP3 -targetting sgRNAs. HSC70 serves as a loading control. (F) Quantification of the invasion potential of CRISPR/Cas9 control and CASP3 -targetted WM793 cells, through wound area measurement (data represent mean with SD of a representative experiment). (G-H) Same as in E-F, for WM852 cells. (I) Quantification of the migration potential of control and CASP3-deficient WM793 cells treated with the pan-caspase inhibitor qVD-OPh (10µM) through wound area measurement (data represent mean with SD of a representative experiment). (J-K) Measurement of caspase-3/7 activation in WM793 ( J ) and WM852 cells ( K ) expressing the caspase reporter VC3AI, and treated with actinomycin D (ActD, 1 µM), ABT-263 (5 µM) and qVD-OPh (10 µM) for 24 h. (L) Analysis by immunoblotting of BAX and BAK expression in BAX / <t>BAK1</t> double knock-out CRISPR/Cas9-edited WM793 cells. HSC70 serves as a loading control. (M-N) Quantification of the migration ( M ) and invasion ( N ) potential of CRISPR/Cas9 control and and BAX / BAK1 double knock-out WM793 cells (data represent mean with SD of a representative experiment).
Lenticrispr V2 Plasmid, supplied by Lucigen Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrispr v2 plasmid/product/Lucigen Corp
Average 90 stars, based on 1 article reviews
lenticrispr v2 plasmid - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
SignaGen lenticrispr v2 plasmids
(A) Immunoblotting analysis of CASP3 expression in WM793 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (B) Quantification of the migration potential of parental and CASP3-deficient WM793 cells using various siRNAs, through wound area measurement (data represent mean with SD of a representative experiment). (C) Analysis by immunoblotting of CASP3 expression in WM852 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (D) Quantification of the migration potential of control and CASP3-deficient WM852 cells using various siRNAs through wound area measurement (data represent mean with SD of a representative experiment). (E) Analysis by immunoblotting of CASP3 expression in CRISPR/Cas9-edited WM793 cells, electroporated with either control or CASP3 -targetting sgRNAs. HSC70 serves as a loading control. (F) Quantification of the invasion potential of CRISPR/Cas9 control and CASP3 -targetted WM793 cells, through wound area measurement (data represent mean with SD of a representative experiment). (G-H) Same as in E-F, for WM852 cells. (I) Quantification of the migration potential of control and CASP3-deficient WM793 cells treated with the pan-caspase inhibitor qVD-OPh (10µM) through wound area measurement (data represent mean with SD of a representative experiment). (J-K) Measurement of caspase-3/7 activation in WM793 ( J ) and WM852 cells ( K ) expressing the caspase reporter VC3AI, and treated with actinomycin D (ActD, 1 µM), ABT-263 (5 µM) and qVD-OPh (10 µM) for 24 h. (L) Analysis by immunoblotting of BAX and BAK expression in BAX / <t>BAK1</t> double knock-out CRISPR/Cas9-edited WM793 cells. HSC70 serves as a loading control. (M-N) Quantification of the migration ( M ) and invasion ( N ) potential of CRISPR/Cas9 control and and BAX / BAK1 double knock-out WM793 cells (data represent mean with SD of a representative experiment).
Lenticrispr V2 Plasmids, supplied by SignaGen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrispr v2 plasmids/product/SignaGen
Average 90 stars, based on 1 article reviews
lenticrispr v2 plasmids - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Promega lenticrispr v2 plasmid
(A) Immunoblotting analysis of CASP3 expression in WM793 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (B) Quantification of the migration potential of parental and CASP3-deficient WM793 cells using various siRNAs, through wound area measurement (data represent mean with SD of a representative experiment). (C) Analysis by immunoblotting of CASP3 expression in WM852 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (D) Quantification of the migration potential of control and CASP3-deficient WM852 cells using various siRNAs through wound area measurement (data represent mean with SD of a representative experiment). (E) Analysis by immunoblotting of CASP3 expression in CRISPR/Cas9-edited WM793 cells, electroporated with either control or CASP3 -targetting sgRNAs. HSC70 serves as a loading control. (F) Quantification of the invasion potential of CRISPR/Cas9 control and CASP3 -targetted WM793 cells, through wound area measurement (data represent mean with SD of a representative experiment). (G-H) Same as in E-F, for WM852 cells. (I) Quantification of the migration potential of control and CASP3-deficient WM793 cells treated with the pan-caspase inhibitor qVD-OPh (10µM) through wound area measurement (data represent mean with SD of a representative experiment). (J-K) Measurement of caspase-3/7 activation in WM793 ( J ) and WM852 cells ( K ) expressing the caspase reporter VC3AI, and treated with actinomycin D (ActD, 1 µM), ABT-263 (5 µM) and qVD-OPh (10 µM) for 24 h. (L) Analysis by immunoblotting of BAX and BAK expression in BAX / <t>BAK1</t> double knock-out CRISPR/Cas9-edited WM793 cells. HSC70 serves as a loading control. (M-N) Quantification of the migration ( M ) and invasion ( N ) potential of CRISPR/Cas9 control and and BAX / BAK1 double knock-out WM793 cells (data represent mean with SD of a representative experiment).
Lenticrispr V2 Plasmid, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lenticrispr v2 plasmid/product/Promega
Average 90 stars, based on 1 article reviews
lenticrispr v2 plasmid - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


(A) Ter119 negative cells and Ter119 positive erythroid cells were purified from wild-type mouse bone marrow cells. G4 levels were tested by flow cytometry using the BG4 antibody that specifically recognizes G4. Quantification is on the right. (B) Bone marrow lineage-negative cells were cultured in Epo medium for 2 days. G4 levels were tested on different days using flow cytometry by the BG4 antibody. Quantification is on the right. (C) CD34+ human HSPCs were cultured in Epo medium for 21 days. The levels of G4 were measured by flow cytometry as in B at the indicated time. Cells at day 7, 14, and 21 represent proerythroblasts, polychromatic to orthochromatic erythroblasts, and orthochromatic to mature red blood cells, respectively. (D) Flow cytometric assays of G4 levels in the indicated bone marrow lineage cells purified from wild-type mice. (E) Quantification of D. (F) Gating strategy of various erythroblasts. Populations I to VI represent proerythroblasts, basophilic erythroblasts, polychromatic erythroblasts, orthochromatic erythroblasts, late orthochromatic to reticulocytes, and mature red blood cells, respectively. (G-H) Flow cytometric assay of G4 level in bone marrow erythroid populations I (G) and V (H) from the indicated mice. Quantification is on the right. (I) Bone marrow lineage negative cells from the indicated mice were cultured in Epo medium for 2 days. G4 levels on different days were measured by flow cytometry using BG4 antibody. Quantification is below the histogram. (J) CD34+ cells were transduced with lentiviral vectors expressing indicated sgRNAs and Cas9. Cells were then harvested for Western blotting of the indicated proteins at day 9 in culture. (K) Quantitative analyses of G4 levels in cells from J using flow cytometric assays. (L) Quantitative analyses of cell death in cells from J using flow cytometric assays. The dead cells are defined as propidium iodide and annexin V double positive. (M) Quantitative analyses of G4 levels in bone marrow mononuclear cells from the patient with DDX41 mutated MDS. All the error bars represent the SEM of the mean. The comparison between two groups was evaluated with 2 tailed t tests, and the comparison among multiple groups was evaluated with 1-way ANOVA tests. * p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. ns: not significant.

Journal: bioRxiv

Article Title: DDX41 dissolves G-quadruplexes to maintain erythroid genome integrity and prevent cGAS-mediated cell death

doi: 10.1101/2024.10.14.617891

Figure Lengend Snippet: (A) Ter119 negative cells and Ter119 positive erythroid cells were purified from wild-type mouse bone marrow cells. G4 levels were tested by flow cytometry using the BG4 antibody that specifically recognizes G4. Quantification is on the right. (B) Bone marrow lineage-negative cells were cultured in Epo medium for 2 days. G4 levels were tested on different days using flow cytometry by the BG4 antibody. Quantification is on the right. (C) CD34+ human HSPCs were cultured in Epo medium for 21 days. The levels of G4 were measured by flow cytometry as in B at the indicated time. Cells at day 7, 14, and 21 represent proerythroblasts, polychromatic to orthochromatic erythroblasts, and orthochromatic to mature red blood cells, respectively. (D) Flow cytometric assays of G4 levels in the indicated bone marrow lineage cells purified from wild-type mice. (E) Quantification of D. (F) Gating strategy of various erythroblasts. Populations I to VI represent proerythroblasts, basophilic erythroblasts, polychromatic erythroblasts, orthochromatic erythroblasts, late orthochromatic to reticulocytes, and mature red blood cells, respectively. (G-H) Flow cytometric assay of G4 level in bone marrow erythroid populations I (G) and V (H) from the indicated mice. Quantification is on the right. (I) Bone marrow lineage negative cells from the indicated mice were cultured in Epo medium for 2 days. G4 levels on different days were measured by flow cytometry using BG4 antibody. Quantification is below the histogram. (J) CD34+ cells were transduced with lentiviral vectors expressing indicated sgRNAs and Cas9. Cells were then harvested for Western blotting of the indicated proteins at day 9 in culture. (K) Quantitative analyses of G4 levels in cells from J using flow cytometric assays. (L) Quantitative analyses of cell death in cells from J using flow cytometric assays. The dead cells are defined as propidium iodide and annexin V double positive. (M) Quantitative analyses of G4 levels in bone marrow mononuclear cells from the patient with DDX41 mutated MDS. All the error bars represent the SEM of the mean. The comparison between two groups was evaluated with 2 tailed t tests, and the comparison among multiple groups was evaluated with 1-way ANOVA tests. * p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. ns: not significant.

Article Snippet: The sgRNAs targeting DDX41 or scrambled sgRNA were cloned into the lentiviral vector lentiCRISPR v2 (Addgene, #52961, encoding Cas9) using the previously reported protocol .

Techniques: Purification, Flow Cytometry, Cell Culture, Transduction, Expressing, Western Blot, Comparison

(A) Epo medium-cultured mouse bone marrow lineage negative HSPCs were treated with 1 μM PDS for the indicated time. Immunofluorescence assays of γ-H2AX were performed, and representative images of the erythroid cells were presented. Scale bar: 5 μm. (B) Flow cytometry assay of the cells in A. (C) Statistical quantification of γH2AX signals in B. (D) Epo medium-cultured mouse bone marrow lineage negative HSPCs were cultured for 1 day, followed by the treatment of 1 μM PDS for 6 hours. Quantitative RT-PCR analyses of indicated ribosome RNAs were performed using different primer sets. (E) Western blotting assays of indicated in cells from D. Actin was used as a loading control. (F) Same as D except that bone marrow lineage negative HSPCs from HBBCre:Ddx41 fl/fl mouse were cultured for 1 day before the quantitative RT-PCR assays. (G) Western blotting assays of the indicated proteins in F. Cells from both day 1 and day 2 cultured cells were analyzed. (H) CD34+ cells were transduced with lentiviral vectors expressing indicated sgRNAs and Cas9. Cells were then harvested for Western blotting of the indicated proteins at day 9 in culture. (I) Immunohistochemical stains of p53 in bone marrow core biopsies from the patient in normal individual. Scale bar: 100 μm. (J) Quantification of γ-H2AX in bone marrow mononuclear cells from the patient in I and 2 control individuals. All the error bars represent the SEM of the mean. The comparison between two groups was evaluated with 2 tailed t tests, and the comparison among multiple groups was evaluated with 1-way ANOVA tests. * p<0.05, **p<0.01, ns: not significant.

Journal: bioRxiv

Article Title: DDX41 dissolves G-quadruplexes to maintain erythroid genome integrity and prevent cGAS-mediated cell death

doi: 10.1101/2024.10.14.617891

Figure Lengend Snippet: (A) Epo medium-cultured mouse bone marrow lineage negative HSPCs were treated with 1 μM PDS for the indicated time. Immunofluorescence assays of γ-H2AX were performed, and representative images of the erythroid cells were presented. Scale bar: 5 μm. (B) Flow cytometry assay of the cells in A. (C) Statistical quantification of γH2AX signals in B. (D) Epo medium-cultured mouse bone marrow lineage negative HSPCs were cultured for 1 day, followed by the treatment of 1 μM PDS for 6 hours. Quantitative RT-PCR analyses of indicated ribosome RNAs were performed using different primer sets. (E) Western blotting assays of indicated in cells from D. Actin was used as a loading control. (F) Same as D except that bone marrow lineage negative HSPCs from HBBCre:Ddx41 fl/fl mouse were cultured for 1 day before the quantitative RT-PCR assays. (G) Western blotting assays of the indicated proteins in F. Cells from both day 1 and day 2 cultured cells were analyzed. (H) CD34+ cells were transduced with lentiviral vectors expressing indicated sgRNAs and Cas9. Cells were then harvested for Western blotting of the indicated proteins at day 9 in culture. (I) Immunohistochemical stains of p53 in bone marrow core biopsies from the patient in normal individual. Scale bar: 100 μm. (J) Quantification of γ-H2AX in bone marrow mononuclear cells from the patient in I and 2 control individuals. All the error bars represent the SEM of the mean. The comparison between two groups was evaluated with 2 tailed t tests, and the comparison among multiple groups was evaluated with 1-way ANOVA tests. * p<0.05, **p<0.01, ns: not significant.

Article Snippet: The sgRNAs targeting DDX41 or scrambled sgRNA were cloned into the lentiviral vector lentiCRISPR v2 (Addgene, #52961, encoding Cas9) using the previously reported protocol .

Techniques: Cell Culture, Immunofluorescence, Flow Cytometry, Quantitative RT-PCR, Western Blot, Control, Transduction, Expressing, Immunohistochemical staining, Comparison

(A) Representative wide-field picture and H&E stains of bone marrow organoid in culture. (B) Whole-mount 3D imaging of the organoids. Imaris was used for cell surface rendering. Organoids were stained with indicated antibodies and subsequently imaged using a laser scanning confocal platform. (C) Confocal immunofluorescence assays of erythroid islands in the iPSC-derived bone marrow organoids (left) and a primary human bone marrow biopsy (right). CD71 was labeled with green for organoids and magenta for primary bone marrow. DAPI: blue. (D) Flow cytometry assays of the organoids using indicated antibodies for various lineages. (E) 10,000 CellVue-labeled donor CD34+ HSPCs were co-incubated with iPSC-derived bone marrow organoids for 3 days in each well of a 96-well plate, followed by an immunofluorescence assay. Representative pictures show the engraftment of donor hematopoietic cells into the organoid. Green, red, and blue represent CD71, CellVue, and DAPI-positive nuclei, respectively. The arrow points to an engrafted CellVue positive cell expressing CD71. (F) Flow cytometry of the organoids using indicated antibodies for various lineages of the engrafted cells in organoids from E. (G) Same as E, except the donor CD34+ cells were transduced with lentiviral vectors expressing Cas9 and indicated sgRNAs before co-incubation. After 3 days, the cells were collected for flow cytometric assays of erythroid and myeloid differentiation of CellVue-positive donor hematopoietic cells and negative iPSC-derived hematopoietic cells. Each data point represents cells combined from 10 organoids. The comparison was evaluated with 1-way ANOVA tests. * p<0.05, **p<0.01. (H) Schematic model of the function of DDX41 during erythropoiesis. The diagram is generated through BioRender.

Journal: bioRxiv

Article Title: DDX41 dissolves G-quadruplexes to maintain erythroid genome integrity and prevent cGAS-mediated cell death

doi: 10.1101/2024.10.14.617891

Figure Lengend Snippet: (A) Representative wide-field picture and H&E stains of bone marrow organoid in culture. (B) Whole-mount 3D imaging of the organoids. Imaris was used for cell surface rendering. Organoids were stained with indicated antibodies and subsequently imaged using a laser scanning confocal platform. (C) Confocal immunofluorescence assays of erythroid islands in the iPSC-derived bone marrow organoids (left) and a primary human bone marrow biopsy (right). CD71 was labeled with green for organoids and magenta for primary bone marrow. DAPI: blue. (D) Flow cytometry assays of the organoids using indicated antibodies for various lineages. (E) 10,000 CellVue-labeled donor CD34+ HSPCs were co-incubated with iPSC-derived bone marrow organoids for 3 days in each well of a 96-well plate, followed by an immunofluorescence assay. Representative pictures show the engraftment of donor hematopoietic cells into the organoid. Green, red, and blue represent CD71, CellVue, and DAPI-positive nuclei, respectively. The arrow points to an engrafted CellVue positive cell expressing CD71. (F) Flow cytometry of the organoids using indicated antibodies for various lineages of the engrafted cells in organoids from E. (G) Same as E, except the donor CD34+ cells were transduced with lentiviral vectors expressing Cas9 and indicated sgRNAs before co-incubation. After 3 days, the cells were collected for flow cytometric assays of erythroid and myeloid differentiation of CellVue-positive donor hematopoietic cells and negative iPSC-derived hematopoietic cells. Each data point represents cells combined from 10 organoids. The comparison was evaluated with 1-way ANOVA tests. * p<0.05, **p<0.01. (H) Schematic model of the function of DDX41 during erythropoiesis. The diagram is generated through BioRender.

Article Snippet: The sgRNAs targeting DDX41 or scrambled sgRNA were cloned into the lentiviral vector lentiCRISPR v2 (Addgene, #52961, encoding Cas9) using the previously reported protocol .

Techniques: Imaging, Staining, Immunofluorescence, Derivative Assay, Labeling, Flow Cytometry, Incubation, Expressing, Transduction, Comparison, Generated

(A) Immunoblotting analysis of CASP3 expression in WM793 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (B) Quantification of the migration potential of parental and CASP3-deficient WM793 cells using various siRNAs, through wound area measurement (data represent mean with SD of a representative experiment). (C) Analysis by immunoblotting of CASP3 expression in WM852 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (D) Quantification of the migration potential of control and CASP3-deficient WM852 cells using various siRNAs through wound area measurement (data represent mean with SD of a representative experiment). (E) Analysis by immunoblotting of CASP3 expression in CRISPR/Cas9-edited WM793 cells, electroporated with either control or CASP3 -targetting sgRNAs. HSC70 serves as a loading control. (F) Quantification of the invasion potential of CRISPR/Cas9 control and CASP3 -targetted WM793 cells, through wound area measurement (data represent mean with SD of a representative experiment). (G-H) Same as in E-F, for WM852 cells. (I) Quantification of the migration potential of control and CASP3-deficient WM793 cells treated with the pan-caspase inhibitor qVD-OPh (10µM) through wound area measurement (data represent mean with SD of a representative experiment). (J-K) Measurement of caspase-3/7 activation in WM793 ( J ) and WM852 cells ( K ) expressing the caspase reporter VC3AI, and treated with actinomycin D (ActD, 1 µM), ABT-263 (5 µM) and qVD-OPh (10 µM) for 24 h. (L) Analysis by immunoblotting of BAX and BAK expression in BAX / BAK1 double knock-out CRISPR/Cas9-edited WM793 cells. HSC70 serves as a loading control. (M-N) Quantification of the migration ( M ) and invasion ( N ) potential of CRISPR/Cas9 control and and BAX / BAK1 double knock-out WM793 cells (data represent mean with SD of a representative experiment).

Journal: bioRxiv

Article Title: Atypical contribution of caspase-3 to melanoma cancer cell motility by regulation of coronin 1B activity

doi: 10.1101/2024.06.27.601010

Figure Lengend Snippet: (A) Immunoblotting analysis of CASP3 expression in WM793 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (B) Quantification of the migration potential of parental and CASP3-deficient WM793 cells using various siRNAs, through wound area measurement (data represent mean with SD of a representative experiment). (C) Analysis by immunoblotting of CASP3 expression in WM852 transfected for 48 h with various CASP3 siRNA (Q1: Qiagen n°1; Q2: Qiagen n°2; S: Sigma-Aldrich; D: Dharmacon) at the indicated concentration. GAPDH serves as a loading control. (D) Quantification of the migration potential of control and CASP3-deficient WM852 cells using various siRNAs through wound area measurement (data represent mean with SD of a representative experiment). (E) Analysis by immunoblotting of CASP3 expression in CRISPR/Cas9-edited WM793 cells, electroporated with either control or CASP3 -targetting sgRNAs. HSC70 serves as a loading control. (F) Quantification of the invasion potential of CRISPR/Cas9 control and CASP3 -targetted WM793 cells, through wound area measurement (data represent mean with SD of a representative experiment). (G-H) Same as in E-F, for WM852 cells. (I) Quantification of the migration potential of control and CASP3-deficient WM793 cells treated with the pan-caspase inhibitor qVD-OPh (10µM) through wound area measurement (data represent mean with SD of a representative experiment). (J-K) Measurement of caspase-3/7 activation in WM793 ( J ) and WM852 cells ( K ) expressing the caspase reporter VC3AI, and treated with actinomycin D (ActD, 1 µM), ABT-263 (5 µM) and qVD-OPh (10 µM) for 24 h. (L) Analysis by immunoblotting of BAX and BAK expression in BAX / BAK1 double knock-out CRISPR/Cas9-edited WM793 cells. HSC70 serves as a loading control. (M-N) Quantification of the migration ( M ) and invasion ( N ) potential of CRISPR/Cas9 control and and BAX / BAK1 double knock-out WM793 cells (data represent mean with SD of a representative experiment).

Article Snippet: 293T cells (1.5 x 10 6 cells in a 10-cm dish) were transfected with lentiCRISPR v2 h CASP3 (see plasmid construct part for design), lentiCRISPR v2 h BAX (Addgene, 129580) and/or LentiCRISPR v2 h BAK1 (Addgene, 129579) plasmids using Lipofectamine 2000.

Techniques: Western Blot, Expressing, Transfection, Concentration Assay, Control, Migration, CRISPR, Activation Assay, Knock-Out